Table 2.
Rates of Endophthalmitis after Intravitreal Anti-Vascular Endothelial Growth Factor Injection in the “No Face Mask” Group Compared with “Universal Face Mask” Group Based on Medication Type
| Medication Type | Injections Administered with No Face Mask N = 294 514 |
Injections Administered with Universal Face Masking N = 211 454 |
Odds Ratio (95% CI) | P Value | |
|---|---|---|---|---|---|
| Bevacizumab (N = 120 532) | Presumed endophthalmitis, N (%) | 18 (0.027%) 1 in 3749 injections |
8 (0.015%) 1 in 6631 injections |
0.57 (0.25–1.30) | 0.174 |
| Ranibizumab (N = 187 539) | Presumed endophthalmitis, N (%) | 23 (0.021%) 1 in 4685 injections |
13 (0.016%) 1 in 6137 injections |
0.76 (0.39–1.51) | 0.435 |
| Aflibercept (N = 197 897) | Presumed endophthalmitis, N (%) | 44 (0.037%) 1 in 2711 injections |
24 (0.031%) 1 in 3276 injections |
0.83 (0.50–1.36) | 0.828 |
CI = confidence interval; N = number.